Molluscum Contagiosum Therapeutics
1. Ycanth patent expiration
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions cause...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233042 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11147790 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11052064 | VERRICA PHARMS | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(9 years from now) | |
| US12290651 | VERRICA PHARMS | Devices and methods for the treatment of body surface disorders |
Feb, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents
2. Zelsuvmi patent expiration
Treatment: Method of administering a nitric oxide releasing active pharmaceutical ingredient to treat and/or prevent viral infection; Method of treating and/or preventing viral infection using a nitric oxide rel...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8956658 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| US8282967 | LNHC | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
May, 2026
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11723858 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US11040006 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10736839 | LNHC | Topical antiviral compositions, delivery systems, and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10322081 | LNHC | Topical antiviral compositions and methods of using the same |
Jul, 2035
(9 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(8 years from now) | |
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US9737561 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9289442 | LNHC | Topical compositions |
Jul, 2032
(6 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(8 years from now) | |
| US10376538 | LNHC | Topical gels and methods of using the same |
Aug, 2030
(4 years from now) | |
| US9526738 | LNHC | Topical gels and methods of using the same |
Sep, 2031
(5 years from now) | |
| US10265334 | LNHC | Anhydrous compositions |
Jul, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents